FI970513A - In vivo mutationer och polymorfismer i den 17q-förknippade susceptibilitetsgenen för bröst- och äggstockscancer - Google Patents
In vivo mutationer och polymorfismer i den 17q-förknippade susceptibilitetsgenen för bröst- och äggstockscancer Download PDFInfo
- Publication number
- FI970513A FI970513A FI970513A FI970513A FI970513A FI 970513 A FI970513 A FI 970513A FI 970513 A FI970513 A FI 970513A FI 970513 A FI970513 A FI 970513A FI 970513 A FI970513 A FI 970513A
- Authority
- FI
- Finland
- Prior art keywords
- ovarian cancer
- breast
- polymorphisms
- susceptibility gene
- relates
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 6
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 6
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 6
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 6
- 210000000481 breast Anatomy 0.000 title abstract 6
- 230000035772 mutation Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 title 1
- 102000054765 polymorphisms of proteins Human genes 0.000 title 1
- 108700040618 BRCA1 Genes Proteins 0.000 abstract 2
- 101150072950 BRCA1 gene Proteins 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 206010069754 Acquired gene mutation Diseases 0.000 abstract 1
- 108700028369 Alleles Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000037439 somatic mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28922194A | 1994-08-12 | 1994-08-12 | |
US30026694A | 1994-09-02 | 1994-09-02 | |
US30810494A | 1994-09-16 | 1994-09-16 | |
US34882494A | 1994-11-29 | 1994-11-29 | |
US40930595A | 1995-03-24 | 1995-03-24 | |
US08/480,784 US5693473A (en) | 1994-08-12 | 1995-06-07 | Linked breast and ovarian cancer susceptibility gene |
US08/483,553 US5709999A (en) | 1994-08-12 | 1995-06-07 | Linked breast and ovarian cancer susceptibility gene |
PCT/US1995/010202 WO1996005306A2 (en) | 1994-08-12 | 1995-08-11 | IN VIVO MUTATIONS AND POLYMORPHISMS IN THE 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE |
Publications (2)
Publication Number | Publication Date |
---|---|
FI970513A0 FI970513A0 (sv) | 1997-02-07 |
FI970513A true FI970513A (sv) | 1997-04-07 |
Family
ID=27569596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI970513A FI970513A (sv) | 1994-08-12 | 1997-02-07 | In vivo mutationer och polymorfismer i den 17q-förknippade susceptibilitetsgenen för bröst- och äggstockscancer |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0705903B2 (sv) |
JP (1) | JP2002503943A (sv) |
CN (1) | CN1172502A (sv) |
AT (1) | ATE201445T1 (sv) |
AU (1) | AU686004B2 (sv) |
CA (1) | CA2196797C (sv) |
DE (1) | DE69521002T3 (sv) |
DK (1) | DK0705903T3 (sv) |
ES (1) | ES2158048T5 (sv) |
FI (1) | FI970513A (sv) |
GR (1) | GR3036322T3 (sv) |
MX (1) | MX9701075A (sv) |
NO (1) | NO970624L (sv) |
NZ (1) | NZ291621A (sv) |
PT (1) | PT705903E (sv) |
WO (1) | WO1996005306A2 (sv) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019369A1 (en) | 1994-01-14 | 1995-07-20 | Vanderbilt University | Method for detection and treatment of breast cancer |
EP0804453A4 (en) * | 1995-01-17 | 2004-08-11 | Univ Vanderbilt | METHOD FOR DETECTING AND TREATING BREAST CANCER |
US5654155A (en) * | 1996-02-12 | 1997-08-05 | Oncormed, Inc. | Consensus sequence of the human BRCA1 gene |
US6951721B2 (en) | 1996-02-12 | 2005-10-04 | Gene Logic Inc. | Method for determining the haplotype of a human BRCA1 gene |
US6838256B2 (en) * | 1996-02-12 | 2005-01-04 | Gene Logic Inc. | Coding sequences of the human BRCA1 gene |
US5891857A (en) * | 1996-02-20 | 1999-04-06 | Vanderbilt University | Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins |
AU4586697A (en) * | 1996-09-20 | 1998-04-14 | Board Of Regents, The University Of Texas System | Compositions and methods comprising bard1 and other brca1 binding proteins |
WO1998031801A1 (en) | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis |
US5965377A (en) * | 1997-03-24 | 1999-10-12 | Baystate Medical Center | Method for determining the presence of mutated BRCA protein |
US6733966B1 (en) | 1997-06-04 | 2004-05-11 | Rijksuniversiteit Te Leiden | Diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination |
US6492109B1 (en) | 1997-09-23 | 2002-12-10 | Gene Logic, Inc. | Susceptibility mutation 6495delGC of BRCA2 |
WO1999024614A1 (en) | 1997-11-06 | 1999-05-20 | Oklahoma Medical Research Foundation | Diagnostic assay for cancer susceptibility |
US6177410B1 (en) | 1997-12-05 | 2001-01-23 | Vanderbilt University | Therapeutic methods for prostate cancer |
US6686163B2 (en) | 1998-05-06 | 2004-02-03 | Gene Logic Inc. | Coding sequence haplotype of the human BRCA1 gene |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
CA2482806A1 (en) | 2002-04-30 | 2003-11-13 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
DK1507556T3 (en) | 2002-05-02 | 2016-09-12 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
ES2545613T3 (es) | 2003-12-01 | 2015-09-14 | Kudos Pharmaceuticals Limited | Inhibidores de reparación de daño en el ADN para el tratamiento del cáncer |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
KR101138862B1 (ko) | 2005-02-14 | 2012-05-14 | 삼성전자주식회사 | 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법 |
KR101206028B1 (ko) | 2005-03-05 | 2012-11-28 | 삼성전자주식회사 | 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이 |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
IL301804A (en) | 2006-05-18 | 2023-05-01 | Caris Mpi Inc | A system and method for determining a personalized medical intervention for a disease stage |
WO2007138355A1 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
EP2188278A1 (en) | 2007-09-14 | 2010-05-26 | AstraZeneca AB | Phthalazinone derivatives |
MX2010004028A (es) | 2007-10-17 | 2010-04-30 | Kudos Pharm Ltd | 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona. |
AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
ES2466565T3 (es) | 2008-08-06 | 2014-06-10 | Biomarin Pharmaceutical Inc. | Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
HUE030800T2 (en) | 2008-10-07 | 2017-05-29 | Astrazeneca Uk Ltd | Pharmaceutical Form No. 514 |
JP2012508577A (ja) | 2008-11-12 | 2012-04-12 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 表現型を決定するためのエキソソームの使用方法およびそのシステム |
UY32790A (es) | 2009-07-15 | 2011-02-28 | Astrazeneca Ab | Compuesto de ftalazinona |
CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
CN104789664A (zh) * | 2015-04-02 | 2015-07-22 | 安诺优达基因科技(北京)有限公司 | 用于乳腺癌易感基因BRCA1和BRCA2的Long-range PCR检测的引物组、方法及试剂盒 |
JP6786066B2 (ja) | 2016-10-07 | 2020-11-18 | 富士通株式会社 | 家系図作成支援プログラム、家系図作成支援方法、及び家系図作成支援装置 |
CN109897852A (zh) * | 2018-07-25 | 2019-06-18 | 广州普世利华科技有限公司 | 基于C2c2的肿瘤相关突变基因的gRNA、检测方法、检测试剂盒 |
CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
US11325906B2 (en) | 2019-07-19 | 2022-05-10 | Astrazeneca Ab | Chemical compounds |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN113388680B (zh) * | 2020-03-14 | 2023-07-04 | 复旦大学附属妇产科医院 | 上皮性卵巢癌靶点ret及其在诊断和治疗中的作用 |
US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
WO2022074617A1 (en) | 2020-10-09 | 2022-04-14 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2022271547A1 (en) | 2021-06-21 | 2022-12-29 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
AU2022392822A1 (en) | 2021-11-18 | 2024-05-02 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
WO2023118085A1 (en) | 2021-12-21 | 2023-06-29 | Astrazeneca Ab | Methods of treating brain tumours and neuroblastomas |
TW202339805A (zh) | 2021-12-28 | 2023-10-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
WO2023194528A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
WO2023194525A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
WO2023194530A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
TW202412859A (zh) | 2022-07-28 | 2024-04-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及雙特異性檢查點抑制劑之組合 |
WO2024116094A1 (en) | 2022-11-30 | 2024-06-06 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugates and dnmt inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
CA1188246A (en) | 1981-08-31 | 1985-06-04 | Jerry L. Gregory | Immobilized microbe recycle apparatus |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
ES2264239T3 (es) * | 1990-06-27 | 2006-12-16 | Princeton University | Complejo de proteinas p53/p90'. |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
WO1994000764A1 (en) * | 1992-06-26 | 1994-01-06 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES | The met proto-oncogene and a method for predicting breast cancer progression |
WO1995019369A1 (en) * | 1994-01-14 | 1995-07-20 | Vanderbilt University | Method for detection and treatment of breast cancer |
EP0804453A4 (en) * | 1995-01-17 | 2004-08-11 | Univ Vanderbilt | METHOD FOR DETECTING AND TREATING BREAST CANCER |
-
1995
- 1995-08-11 NZ NZ291621A patent/NZ291621A/en not_active IP Right Cessation
- 1995-08-11 CA CA002196797A patent/CA2196797C/en not_active Expired - Lifetime
- 1995-08-11 EP EP95305605A patent/EP0705903B2/en not_active Expired - Lifetime
- 1995-08-11 AT AT95305605T patent/ATE201445T1/de not_active IP Right Cessation
- 1995-08-11 ES ES95305605T patent/ES2158048T5/es not_active Expired - Lifetime
- 1995-08-11 JP JP50750796A patent/JP2002503943A/ja active Pending
- 1995-08-11 CN CN95195413.XA patent/CN1172502A/zh active Pending
- 1995-08-11 AU AU33212/95A patent/AU686004B2/en not_active Expired
- 1995-08-11 PT PT95305605T patent/PT705903E/pt unknown
- 1995-08-11 WO PCT/US1995/010202 patent/WO1996005306A2/en not_active Application Discontinuation
- 1995-08-11 MX MX9701075A patent/MX9701075A/es unknown
- 1995-08-11 DE DE69521002T patent/DE69521002T3/de not_active Expired - Lifetime
- 1995-08-11 DK DK95305605T patent/DK0705903T3/da active
-
1997
- 1997-02-07 FI FI970513A patent/FI970513A/sv unknown
- 1997-02-11 NO NO970624A patent/NO970624L/no not_active Application Discontinuation
-
2001
- 2001-08-06 GR GR20010401173T patent/GR3036322T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK0705903T3 (da) | 2001-08-27 |
EP0705903B2 (en) | 2009-08-12 |
CA2196797A1 (en) | 1996-02-22 |
NZ291621A (en) | 1998-09-24 |
DE69521002D1 (de) | 2001-06-28 |
CA2196797C (en) | 2000-10-10 |
ES2158048T3 (es) | 2001-09-01 |
WO1996005306A2 (en) | 1996-02-22 |
DE69521002T2 (de) | 2001-11-15 |
NO970624L (no) | 1997-04-14 |
NO970624D0 (no) | 1997-02-11 |
GR3036322T3 (en) | 2001-11-30 |
AU3321295A (en) | 1996-03-07 |
MX9701075A (es) | 1998-03-31 |
PT705903E (pt) | 2001-11-30 |
ES2158048T5 (es) | 2009-11-04 |
DE69521002T3 (de) | 2010-02-25 |
CN1172502A (zh) | 1998-02-04 |
WO1996005306A3 (en) | 1996-03-14 |
ATE201445T1 (de) | 2001-06-15 |
JP2002503943A (ja) | 2002-02-05 |
EP0705903B1 (en) | 2001-05-23 |
EP0705903A1 (en) | 1996-04-10 |
AU686004B2 (en) | 1998-01-29 |
FI970513A0 (sv) | 1997-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI970513A (sv) | In vivo mutationer och polymorfismer i den 17q-förknippade susceptibilitetsgenen för bröst- och äggstockscancer | |
FI970514A0 (sv) | 17q:-förknippad susceptibilitetsgen för bröst- och äggstockscancer | |
NO982785L (no) | Kromosom 13-koblet brystkreftmottagelighetsgen | |
EP1260520A3 (en) | Chromosome 13-linked breast cancer susceptibility gene | |
DE60135022D1 (de) | Antitumoraktivität zeigendes runx3-gen und dessen verwendung | |
WO1998025125A3 (en) | Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus | |
MX9701074A (es) | Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q. |